May 10, 2018 — Results from the clinical study to evaluate Imricor’s Vision-MR Ablation Catheter for the treatment of atrial flutter under real-time magnetic resonance imaging (MRI) guidance will be presented at the 2018 Heart Rhythm Society (HRS) conference, May 9-12 in Boston. Philipp Sommer, M.D., will present the study results.
The single-center study enrolled 35 patients and was sponsored by the University of Leipzig Heart Center in Leipzig, Germany. Prof. Gerhard Hindricks, M.D., head of the Department of Electrophysiology at the Helios Leipzig Heart Center, was the principal investigator. Results from the study will be submitted to support the CE mark approval process for the Vision-MR Ablation Catheter. Publication of study results will follow later this spring.
Imricor’s Vision-MR Ablation Catheter, when used with the Advantage-MR EP Recorder/Stimulator System, allows physicians to perform cardiac ablations under MRI guidance, offering a radiation-free environment for patients and physicians. Intraprocedural MR imaging allows for real-time soft tissue imaging of the cardiac anatomy and substrate. This has the potential to improve first-time success rates of ablation procedures by providing lesion visualization and verification. In addition, real-time assessment of the cardiac substrate has the potential to allow physicians to deliver individualized ablation strategies.
The Advantage-MR EP Recorder/Stimulator System has received CE mark approval; it has not yet been approved for use in the United States. The Vision-MR Ablation Catheter has been approved as an investigational device for clinical studies in Europe. All other Imricor devices are not yet approved for use in humans.
For more information: www.imricor.com